Commercial strategy for Gilead’s Covid-19 drug-to-be remdesivir remains opaque, as chief O’Day emphasizes responsibility

In his opening remarks on Thursday, Gilead chief Daniel O?Day did us all a favor, truncating his commentary on the quarter gone by to set aside more time to discuss in detail remdesivir: the compound at the heart of efforts to combat Covid-19. But the big question remained ? does…

Click to view original post